Keros rebuilt around a muscle-wasting ActA/ActB trap after a PAH safety halt; the case turns on whether Phase 1 PD signals in healthy volunteers translate to functional benefit in DMD

Bull

A positive outcome would show statistically and clinically meaningful improvements in functional endpoints such as North Star Ambulatory Assessment scores, timed function tests, or muscle volume by MRI, alongside a clean safety profile, confirming that the ActA/ActB dual trap mechanism drives real functional benefit in a genetically defined muscle-wasting disease. This would validate the Phase 1 PD-to-efficacy translation hypothesis, de-risk the broader rinvatercept platform across neuromuscular indications including ALS, and potentially attract partnership interest or accelerate regulatory discussions for a pivotal program.

Bear

The most likely failure mode is a disconnect between the robust PD signals seen in healthy volunteers — who have intact muscle architecture — and DMD patients whose muscle is progressively replaced by fibrotic and fatty tissue, limiting the substrate on which an anabolic ActA/ActB trap can act. Secondary failure modes include dose selection errors that produce inadequate target engagement in the patient population, a safety signal related to hemoglobin elevation or off-target effects amplified in a pediatric population, or functional endpoints that show biomarker changes without patient-relevant improvement, leaving the thesis unresolved.